Industry teaser promotions at American Society of Hospital Pharmacists mid-year meeting and exhibit included 3M's Maxair pirbuterol acetate autohaler. The asthma drug, approved Nov. 30, was developed with Boehringer Ingelheim. Maxair will be marketed by 3M in 1993 as the only breath-activated, pressurized metered- dose inhaler. Other "coming soon" promotions included Rhone- Poulenc Rorer's low molecular weight heparin injection Lovenox (enoxaparin), which has been "approvable" at FDA since Nov. 20; Wallace Labs' felbamate anticonvulsant, which goes before an advisory committee Dec. 14; an unnamed Schwarz Pharma cardiovascular drug -- the company has an NDA pending for Monoket ISMO tablets for angina; Marion Merrell Dow's Targocid (teicoplanin) once-daily injectable antibiotic for gram-positive infections; and Lederle's beta lactam/beta-lactamase inhibitor Tazosyn (piperacillin/tazobactam) for severe hospital infections.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth